Last reviewed · How we verify

OBR — Competitive Intelligence Brief

OBR (OBR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (depot formulation). Area: Psychiatry / Neurology.

marketed Atypical antipsychotic (depot formulation) Dopamine D2 receptor (partial agonist) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

OBR (OBR) — Otsuka Pharmaceutical Development & Commercialization, Inc.. OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OBR TARGET OBR Otsuka Pharmaceutical Development & Commercialization, Inc. marketed Atypical antipsychotic (depot formulation) Dopamine D2 receptor (partial agonist)
Antidepressant + Aripiprazole Antidepressant + Aripiprazole Bristol-Myers Squibb phase 3 Antidepressant + atypical antipsychotic combination Serotonin/norepinephrine reuptake transporters (antidepressant component); dopamine D2 receptor partial agonist (aripiprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (depot formulation) class)

  1. Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OBR — Competitive Intelligence Brief. https://druglandscape.com/ci/obr. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: